Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025

Phase 1AN9025Positive

AI Analysis

Summary

Adlai Nortye announced the first patient has been dosed in the intermittent weekly dosing arm of a Phase 1 clinical trial for AN9025, a pan-RAS(ON) inhibitor.

Clinical Trial Data

Phase

Phase 1

Outcome Details

First patient dosed in intermittent weekly dosing arm

Importance:3/10

Sentiment:

0.30

Phase 1 TrialPan-RAS InhibitorDosing Milestone

Related Companies

$INTI $GBCYD $TRAX

Read the original article

Published by GlobeNewswire Clinical Studies on July 16, 2026 11:00 AM

Read Original